Drug Profile
TRM 147
Latest Information Update: 26 Mar 2007
Price :
$50
*
At a glance
- Originator Terumo
- Developer Japan Tobacco; Terumo
- Class Antiplatelets; Vascular disorder therapies
- Mechanism of Action GPIIb-IIIa antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Arterial thrombosis
Most Recent Events
- 31 Oct 2006 Discontinued - Preclinical for Arterial thrombosis in Japan (PO)
- 21 Sep 1998 Japan Tobacco has licensed TRM 147 from Terumo for worldwide, including Japan
- 06 Nov 1996 New profile